SST and pancreatic neuroendocrine tumor: Although somatostatin analogs were developed primarily for reducing the levels of circulating hormones causing typical endocrine syndromes, the results of PROMID [18] and CLARINET [19] open-label studies confirmed that somatostatin analogs have a positive impact on progression-free survival in pancreatic and non-pancreatic neuroendocrine tumors, due to their anti-proliferative effect [20].